NCT04209634View on ClinicalTrials.gov

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

November 9, 2021

Study Completion Date

May 2, 2024

Conditions
CD55-deficient Protein-losing EnteropathyCHAPLE
Interventions
DRUG

Pozelimab

Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.

Trial Locations (3)

10330

Regeneron Research Site, Pathum Wan

20892

Regeneron Research Site, Bethesda

34890

Regeneron Research Site, Istanbul

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04209634 - Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) | Biotech Hunter | Biotech Hunter